AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 184 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $423,000 | -79.7% | 22,000 | -68.8% | 0.01% | -79.4% |
Q2 2019 | $2,083,000 | +3.6% | 70,484 | +66.6% | 0.07% | +4.6% |
Q1 2019 | $2,010,000 | +134.5% | 42,313 | +78.3% | 0.06% | +116.7% |
Q4 2018 | $857,000 | -39.5% | 23,735 | +3.2% | 0.03% | -28.6% |
Q3 2018 | $1,416,000 | -8.8% | 23,001 | +0.1% | 0.04% | -8.7% |
Q2 2018 | $1,552,000 | +20.0% | 22,969 | -3.6% | 0.05% | +4.5% |
Q1 2018 | $1,293,000 | -10.4% | 23,837 | -1.3% | 0.04% | -10.2% |
Q4 2017 | $1,443,000 | +16.1% | 24,158 | -5.6% | 0.05% | +16.7% |
Q3 2017 | $1,243,000 | -4.6% | 25,591 | +3.2% | 0.04% | -14.3% |
Q2 2017 | $1,303,000 | +15.9% | 24,800 | +0.0% | 0.05% | +19.5% |
Q1 2017 | $1,124,000 | -24.2% | 24,790 | -36.7% | 0.04% | -19.6% |
Q4 2016 | $1,482,000 | -63.2% | 39,165 | -63.3% | 0.05% | -29.2% |
Q3 2016 | $4,027,000 | -63.7% | 106,715 | -69.9% | 0.07% | -66.7% |
Q1 2015 | $11,096,000 | +105.6% | 354,045 | +91.5% | 0.22% | +91.2% |
Q4 2014 | $5,397,000 | – | 184,905 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |